Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inari Medical Inc (NQ: NARI )

48.74 +0.34 (+0.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 589,462
Open 48.53
Bid (Size) 45.42 (1)
Ask (Size) 49.16 (2)
Prev. Close 48.40
Today's Range 48.17 - 48.92
52wk Range 36.81 - 67.13
Shares Outstanding 54,313,676
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PEERLESS Results Show Superiority of FlowTriever® Compared to Catheter-Directed Thrombolytics for Intermediate-Risk Pulmonary Embolism
Primary endpoint win driven by both hard clinical outcomes and hospital resource utilization 
From Inari Medical, Inc.
Via GlobeNewswire
Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday
Via Benzinga

Performance

YTD
-25.88%
-25.88%
1 Month
+17.14%
+17.14%
3 Month
+5.57%
+5.57%
6 Month
+16.49%
+16.49%
1 Year
+0.91%
+0.91%

More News

Read More
Key Takeaways From Inari Medical Analyst Ratings
Via Benzinga
Inari Medical Reports Third Quarter 2024 Financial Results
From Inari Medical, Inc.
Via GlobeNewswire
Inari Medical's Earnings: A Preview
Via Benzinga
Breaking Down Inari Medical: 9 Analysts Share Their Views
Via Benzinga
Inari Medical Announces Partnership with AVF and NBCA on DEFIANCE Trial
From Inari Medical, Inc.
Via GlobeNewswire
Inari Medical to Host Analyst and Investor Meeting Following PEERLESS RCT Presentation
From Inari Medical, Inc.
Via GlobeNewswire
Inari Medical to Announce Third Quarter 2024 Financial Results
From Inari Medical, Inc.
Via GlobeNewswire
Expert Outlook: Inari Medical Through The Eyes Of 9 Analysts
Via Benzinga
Breaking Down Inari Medical: 7 Analysts Share Their Views
Via Benzinga
Deep Dive Into Inari Medical Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
Kaskela Law LLC Announces Shareholder Investigation of Inari Medical, Inc. (NASDAQ: NARI) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024
From Inari Medical, Inc.
Via GlobeNewswire
FDA Classifies Recall Of Inari Medical's Large Vessel Clot Removal Catheter Device As Most Serious
Via Benzinga
Exposures Product Safety
Inari Medical to Present at Upcoming Investor Conferences
From Inari Medical, Inc.
Via GlobeNewswire
7 Leading MedTech Stocks for Next-Gen Health Solutions
Via InvestorPlace
NARI Stock Earnings: Inari Medical Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Inari Medical Announces Chief Financial Officer Retirement and Succession Plan
From Inari Medical, Inc.
Via GlobeNewswire
Inari Medical Reports Second Quarter 2024 Financial Results
From Inari Medical, Inc.
Via GlobeNewswire
Inari Medical to Announce Second Quarter 2024 Financial Results
From Inari Medical, Inc.
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Inari
From Faruqi & Faruqi LLP
Via GlobeNewswire
NARI Investors Have Opportunity to Lead Inari Medical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Inari Medical, Inc. (NARI)
From The Law Offices of Frank R. Cruz
Via Business Wire
NARI Investors Have Opportunity to Lead Inari Medical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.